Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
For more information about this clinical trial, click here
Schema & Eligibility SWOG S1803
CoxHealth Medical Center, Springfield, MO
Mercy Hospital, Springfield, MO
Mercy Clinic Cancer & Hematology, Rolla, MO
Ask your physician about participating in this clinical trial or call us.